Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PAVmed ( (PAVM) ) has issued an announcement.
On March 27, 2026, PAVmed Inc. held a special meeting at which stockholders representing about 54.1% of voting power approved the issuance of common shares tied to 60,000 Series D Convertible Preferred shares and an amended senior secured convertible note, both stemming from a February 3, 2026 private placement and related refinancing. These approvals clear the way for PAVmed to convert recent preferred and debt financings into equity, which may strengthen its balance sheet but also increase share dilution for existing investors.
At the same meeting, stockholders approved an amendment to the certificate of incorporation allowing removal of directors, with or without cause, by a majority of outstanding voting power, a change that enhances shareholder influence over board composition. Investors also backed a major expansion of the 2014 Long-Term Incentive Equity Plan, increasing available shares from 213,517 to 1,713,517, bolstering PAVmed’s ability to use equity-based compensation to attract and retain talent while adding to potential future dilution.
The most recent analyst rating on (PAVM) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative cash flows). Offsetting factors include improving near-term technical setup and generally positive operational/financing developments from the earnings call and recent capital restructuring, though valuation signals remain limited due to negative earnings and no dividend.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. is a publicly traded medical technology company that develops and commercializes minimally invasive devices and diagnostics. The company accesses capital through preferred stock, convertible notes, and equity incentive plans, reflecting a financing strategy common among growth-stage medtech firms seeking to fund product development and commercialization.
Average Trading Volume: 1,024,553
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.38M
See more insights into PAVM stock on TipRanks’ Stock Analysis page.